Nov 7, 2017 4:20 pm EST SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
Oct 5, 2017 8:30 am EDT SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017
Sep 27, 2017 8:30 am EDT SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017
Aug 15, 2017 8:00 am EDT “THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)
Aug 14, 2017 8:00 am EDT SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting
Aug 8, 2017 4:25 pm EDT SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update
Aug 3, 2017 4:05 pm EDT SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
Jun 15, 2017 8:30 am EDT New Study Further Demonstrates In Vitro Activity of SCYNEXIS’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains
